Advertisement
Screener

ORIC PHARMACEUTICALS, INC. (ORIC) Increase (Decrease) in Prepaid Expense and Other Assets

2.8 / 5 stars · 68/120 Roast Me

ORIC PHARMACEUTICALS, INC. Increase (Decrease) in Prepaid Expense and Other Assets

ORIC PHARMACEUTICALS, INC. (ORIC) reported Increase (Decrease) in Prepaid Expense and Other Assets of $658.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-03

  • ORIC PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$21.00K, a 103.95% decline year-over-year.
  • ORIC PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $679.00K, a 18.09% increase year-over-year.
  • ORIC PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$2.11M.
  • ORIC PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$782.00K.
  • ORIC PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$1.79M.
  • ORIC PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$143.00K.
  • ORIC PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$1.62M.
  • ORIC PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$1.03M.
Period endIncrease (Decrease) in Prepaid Expense and Other Assets 3 monthIncrease (Decrease) in Prepaid Expense and Other Assets 6 monthIncrease (Decrease) in Prepaid Expense and Other Assets 9 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 month
2026-06-30-$21.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03
$658.00K
10-Q · filed 2026-08-03
-$1.45M
derived: sum of 3 quarters · filed 2026-08-03
-$2.24M
derived: sum of 4 quarters · filed 2026-08-03
2026-03-31$679.00K
10-Q · filed 2026-05-04
-$1.43M
derived: sum of 2 quarters · filed 2026-05-04
-$2.21M
derived: sum of 3 quarters · filed 2026-05-04
-$1.68M
derived: sum of 4 quarters · filed 2026-08-03
2025-12-31-$2.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
-$2.89M
derived: sum of 2 quarters · filed 2026-02-23
-$2.36M
derived: sum of 3 quarters · filed 2026-08-03
-$1.79M
10-K · filed 2026-02-23
2025-09-30-$782.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$250.00K
derived: sum of 2 quarters · filed 2026-08-03
$325.00K
10-Q · filed 2025-11-13
-$1.03M
derived: sum of 4 quarters · filed 2026-08-03
2025-06-30$532.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03
$1.11M
10-Q · filed 2026-08-03
-$247.00K
derived: sum of 3 quarters · filed 2026-08-03
-$1.88M
derived: sum of 4 quarters · filed 2026-08-03
2025-03-31$575.00K
10-Q · filed 2026-05-04
-$779.00K
derived: sum of 2 quarters · filed 2026-05-04
-$2.41M
derived: sum of 3 quarters · filed 2026-05-04
-$1.98M
derived: sum of 4 quarters · filed 2026-05-04
2024-12-31-$1.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
-$2.99M
derived: sum of 2 quarters · filed 2026-02-23
-$2.55M
derived: sum of 3 quarters · filed 2026-02-23
-$143.00K
10-K · filed 2026-02-23
2024-09-30-$1.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$1.20M
derived: sum of 2 quarters · filed 2025-11-13
$1.21M
10-Q · filed 2025-11-13
$206.00K
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$434.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
$2.84M
10-Q · filed 2025-08-12
$1.84M
derived: sum of 3 quarters · filed 2025-08-12
$2.12M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$2.41M
10-Q · filed 2025-05-05
$1.40M
derived: sum of 2 quarters · filed 2025-05-05
$1.68M
derived: sum of 3 quarters · filed 2025-05-05
$1.89M
derived: sum of 4 quarters · filed 2025-05-05
2023-12-31-$1.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18
-$728.00K
derived: sum of 2 quarters · filed 2025-02-18
-$517.00K
derived: sum of 3 quarters · filed 2025-02-18
-$1.62M
10-K · filed 2025-02-18
2023-09-30$277.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$488.00K
derived: sum of 2 quarters · filed 2024-11-12
-$615.00K
10-Q · filed 2024-11-12
-$1.89M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$211.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
-$892.00K
10-Q · filed 2024-08-12
-$2.17M
derived: sum of 3 quarters · filed 2024-08-12
-$4.03M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$1.10M
10-Q · filed 2024-05-06
-$2.38M
derived: sum of 2 quarters · filed 2024-05-06
-$4.25M
derived: sum of 3 quarters · filed 2024-05-06
-$2.67M
derived: sum of 4 quarters · filed 2024-05-06
2022-12-31-$1.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11
-$3.14M
derived: sum of 2 quarters · filed 2024-03-11
-$1.57M
derived: sum of 3 quarters · filed 2024-03-11
-$1.03M
10-K · filed 2024-03-11
2022-09-30-$1.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
-$289.00K
derived: sum of 2 quarters · filed 2023-11-06
$247.00K
10-Q · filed 2023-11-06
$115.00K
derived: sum of 4 quarters · filed 2023-11-06
2022-06-30$1.58M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$2.11M
10-Q · filed 2023-08-10
$1.98M
derived: sum of 3 quarters · filed 2023-08-10
$1.28M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$536.00K
10-Q · filed 2023-05-08
$404.00K
derived: sum of 2 quarters · filed 2023-05-08
-$299.00K
derived: sum of 3 quarters · filed 2023-05-08
$826.00K
derived: sum of 4 quarters · filed 2023-05-08
2021-12-31-$132.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16
-$835.00K
derived: sum of 2 quarters · filed 2023-03-16
$290.00K
derived: sum of 3 quarters · filed 2023-03-16
-$1.14M
10-K · filed 2023-03-16
2021-09-30-$703.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
$422.00K
derived: sum of 2 quarters · filed 2022-11-07
-$1.01M
10-Q · filed 2022-11-07
-$351.00K
derived: sum of 4 quarters · filed 2022-11-07
2021-06-30$1.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
-$307.00K
10-Q · filed 2022-08-11
$352.00K
derived: sum of 3 quarters · filed 2022-08-11
$205.00K
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$1.43M
10-Q · filed 2022-05-09
-$773.00K
derived: sum of 2 quarters · filed 2022-05-09
-$920.00K
derived: sum of 3 quarters · filed 2022-05-09
$879.00K
derived: sum of 4 quarters · filed 2022-05-09
2020-12-31$659.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21
$512.00K
derived: sum of 2 quarters · filed 2022-03-21
$2.31M
derived: sum of 3 quarters · filed 2022-03-21
$2.26M
10-K · filed 2022-03-21
2020-09-30-$147.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$1.65M
derived: sum of 2 quarters · filed 2021-11-08
$1.60M
10-Q · filed 2021-11-08
$1.59M
derived: sum of 4 quarters · filed 2022-03-21
2020-06-30$1.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10
$1.75M
10-Q · filed 2021-08-10
$1.74M
derived: sum of 3 quarters · filed 2022-03-21
$1.38M
derived: sum of 4 quarters · filed 2022-03-21
2020-03-31-$53.00K
10-Q · filed 2021-05-06
-$64.00K
derived: sum of 2 quarters · filed 2022-03-21
-$416.00K
derived: sum of 3 quarters · filed 2022-03-21
-$576.00K
derived: sum of 4 quarters · filed 2022-03-21
2019-12-31-$11.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21
-$363.00K
derived: sum of 2 quarters · filed 2022-03-21
-$523.00K
derived: sum of 3 quarters · filed 2022-03-21
-$234.00K
10-K · filed 2022-03-21
2019-09-30-$352.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$512.00K
derived: sum of 2 quarters · filed 2020-11-05
-$223.00K
10-Q · filed 2020-11-05
2019-06-30-$160.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05
$129.00K
10-Q · filed 2020-08-05
2019-03-31$289.00K
10-Q · filed 2020-05-20
2018-12-31$297.00K
10-K · filed 2021-03-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kardigan, Inc. (KARD)United States$1.346B
Tyra Biosciences, Inc. (TYRA)United States$1.337B-12.83
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
OMEROS CORP (OMER)United States$1.456B5.50
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
Avalyn Pharma Inc. (AVLN)United States$1.267B
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Innoviva, Inc. (INVA)United States$1.493B4.62